Journal article icon

Journal article

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

Abstract:

PURPOSE: PTK787/ZK 222584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerability and promising activity in early-phase studies, which led to a phase III trial in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4). PATIENTS AND METHODS: Patients (N = 1,168) with previously untreated metastatic colorectal cancer were randomly assigned 1:1 to receive FOLFOX4 plus PTK/ZK or placebo (ClinicalTrials.gov identifier: NCT00056459). Strati...

Expand abstract

Actions


Access Document


Publisher copy:
10.1200/jco.2010.29.4496

Authors


Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology More from this journal
Volume:
29
Issue:
15
Pages:
1997-2003
Publication date:
2011-05-01
DOI:
EISSN:
1527-7755
ISSN:
0732-183X

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP